89 research outputs found
The impact of a standardised intramuscular sedation protocol for acute behavioural disturbance in the emergency department
Background: Acute behavioural disturbance (ABD) is an increasing problem in emergency departments. This study aimed to determine the impact of a structured intramuscular (IM) sedation protocol on the duration of ABD in the emergency department. Methods: A historical control study was undertaken comparing 58 patients who required physical restraint and parenteral sedation with the structured IM sedation protocol, to 73 historical controls treated predominantly by intravenous sedation, according to individual clinician preference. The primary outcome was the duration of the ABD defined as the time security staff were required. Secondary outcomes were the requirement for additional sedation, drug related-adverse effects and patient and staff injuries. Results: The median duration of the ABD in patients with the new sedation protocol was 21 minutes (IQR: 15 to 35 minutes; Range: 5 to 78 minutes) compared to a median duration of 30 minutes (IQR: 15 to 50 minutes; Range: 5 to 135 minutes) in the historical controls which was significantly different (p = 0.03). With IM sedation only 27 of 58 patients (47%; 95% CI: 34% to 60%) required further sedation compared to 64 of 73 historical controls (88%; 95%CI: 77% to 94%). There were six (10%) drug-related adverse events with the new IM protocol [oxygen desaturation (5), oxygen desaturation/airway obstruction (1)] compared to 10 (14%) in the historical controls [oxygen desaturation (5), hypoventilation (4) and aspiration (1)]. Injuries to staff occurred with three patients using the new sedation protocol and in seven of the historical controls. Two patients were injured during the new protocol and two of the historical controls. Conclusion: The use of a standardised IM sedation protocol was simple, more effective and as safe for management of ABD compared to predominantly intravenous sedation
Impact Factor: outdated artefact or stepping-stone to journal certification?
A review of Garfield's journal impact factor and its specific implementation
as the Thomson Reuters Impact Factor reveals several weaknesses in this
commonly-used indicator of journal standing. Key limitations include the
mismatch between citing and cited documents, the deceptive display of three
decimals that belies the real precision, and the absence of confidence
intervals. These are minor issues that are easily amended and should be
corrected, but more substantive improvements are needed. There are indications
that the scientific community seeks and needs better certification of journal
procedures to improve the quality of published science. Comprehensive
certification of editorial and review procedures could help ensure adequate
procedures to detect duplicate and fraudulent submissions.Comment: 25 pages, 12 figures, 6 table
True 99th centile of high sensitivity cardiac troponin for hospital patients: prospective, observational cohort study?
OBJECTIVE
To determine the distribution, and specifically the true 99th centile, of high sensitivity cardiac troponin I
(hs-cTnI) for a whole hospital population by applying the hs-cTnI assay currently used routinely at a large
teaching hospital.
DESIGN
Prospective, observational cohort study.
SETTING
University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom, between 29
June 2017 and 24 August 2017.
PARTICIPANTS
20000 consecutive inpatients and outpatients undergoing blood tests for any clinical reason.
Hs-cTnI concentrations were measured in all study participants and nested for analysis except when the
supervising doctor had requested hs-cTnI for clinical reasons.
MAIN OUTCOME MEASURES
Distribution of hs-cTnI concentrations of all study participants and specifically the 99th centile.
RESULTS
The 99th centile of hs-cTnI for the whole population was 296 ng/L compared with the manufacturer’s
quoted level of 40 ng/L (currently used clinically as the upper limit of normal; ULN). Hs-cTnI
concentrations were greater than 40 ng/L in one in 20 (5.4%, n=1080) of the total population. After
excluding participants diagnosed as having acute myocardial infarction (n=122) and those in whom
hs-cTnI was requested for clinical reasons (n=1707), the 99th centile was 189 ng/L for the remainder
(n=18171). The 99th centile was 563 ng/L for inpatients (n=4759) and 65 ng/L for outpatients
(n=9280). Patients from the emergency department (n=3706) had a 99th centile of 215 ng/L, with 6.07%
(n=225) greater than the recommended ULN. 39.02% (n=48) of all patients from the critical care units
(n=123) and 14.16% (n=67) of all medical inpatients had an hs-cTnI concentration greater than the
recommended ULN.
CONCLUSIONS
Of 20000 consecutive patients undergoing a blood test for any clinical reason at our hospital, one in 20
had an hs-cTnI greater than the recommended ULN. These data highlight the need for clinical staff to
interpret hs-cTnI concentrations carefully, particularly when applying the recommended ULN to diagnose
acute myocardial infarction, in order to avoid misdiagnosis in the absence of an appropriate clinical
presentation.
TRIAL REGISTRATION
Clinicaltrials.gov NCT0304778
Association and Interaction Analyses of GABBR1 and GABBR2 with Nicotine Dependence in European- and African-American Populations
Previous studies have demonstrated that the Îł-aminobutyric acid type B (GABAB) receptor plays an essential role in modulating neurotransmitter release and regulating the activity of ion channels and adenyl cyclase. However, whether the naturally occurring polymorphisms in the two GABAB receptor subunit genes interact with each other to alter susceptibility to nicotine dependence (ND) remains largely unknown. In this study, we genotyped 5 and 33 single nucleotide polymorphisms (SNPs) for GABAB receptor subunit 1 and 2 genes (GABBR1, GABBR2), respectively, in a sample of 2037 individuals from 602 nuclear families of African- American (AA) or European-American (EA) origin. We conducted association analyses to determine (1) the association of each subunit gene with ND at both the individual SNP and haplotype levels and (2) the collective effect(s) of SNPs in both GABAB subunits on the development of ND. Several individual SNPs and haplotypes in GABBR2 were significantly associated with ND in both ethnic samples. Two haplotypes in AAs and one haplotype in EAs showed a protective effect against ND, whilst two other haplotypes in AAs and three haplotypes in EAs showed a risk effect for developing ND. Interestingly, these significant haplotypes were confined to two regions of GABBR2 in the AA and EA samples. Additionally, we found two minor haplotypes in GABBR1 to be positively associated with Heaviness of Smoking Index (HSI) in the EA sample. Finally, we demonstrated the presence of epistasis between GABBR1 and GABBR2 for developing ND. The variants of GABBR1 and GABBR2 are significantly associated with ND, and the involvement of GABBR1 is most likely through its interaction with GABBR2, whereas GABBR2 polymorphisms directly alter susceptibility to ND. Future studies are needed with more dense SNP coverage of GABBR1 and GABBR2 to verify the epistatic effects of the two subunit genes
Predictors of Multidrug- and Extensively Drug-Resistant Tuberculosis in a High HIV Prevalence Community
BACKGROUND: Multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB) have emerged in high-HIV-prevalence settings, which generally lack laboratory infrastructure for diagnosing TB drug resistance. Even where available, inherent delays with current drug-susceptibility testing (DST) methods result in clinical deterioration and ongoing transmission of MDR and XDR-TB. Identifying clinical predictors of drug resistance may aid in risk stratification for earlier treatment and infection control. METHODS: We performed a retrospective case-control study of patients with MDR (cases), XDR (cases) and drug-susceptible (controls) TB in a high-HIV-prevalence setting in South Africa to identify clinical and demographic risk factors for drug-resistant TB. Controls were selected in a 1:1:1 ratio and were not matched. We calculated odds ratios (OR) and performed multivariate logistic regression to identify independent predictors. RESULTS: We enrolled 116, 123 and 139 patients with drug-susceptible, MDR, and XDR-TB. More than 85% in all three patient groups were HIV-infected. In multivariate analysis, MDR and XDR-TB were each strongly associated with history of TB treatment failure (adjusted OR 51.7 [CI 6.6-403.7] and 51.5 [CI 6.4-414.0], respectively) and hospitalization more than 14 days (aOR 3.8 [CI 1.1-13.3] and 6.1 [CI 1.8-21.0], respectively). Prior default from TB treatment was not a risk factor for MDR or XDR-TB. HIV was a risk factor for XDR (aOR 8.2, CI 1.3-52.6), but not MDR-TB. Comparing XDR with MDR-TB patients, the only significant risk factor for XDR-TB was HIV infection (aOR 5.3, CI 1.0-27.6). DISCUSSION: In this high-HIV-prevalence and drug-resistant TB setting, a history of prolonged hospitalization and previous TB treatment failure were strong risk factors for both MDR and XDR-TB. Given high mortality observed among patients with HIV and drug-resistant TB co-infection, previously treated and hospitalized patients should be considered for empiric second-line TB therapy while awaiting confirmatory DST results in settings with a high-burden of MDR/XDR-TB
Functioning of the dimeric GABA(B) receptor extracellular domain revealed by glycan wedge scanning
The G-protein-coupled receptor (GPCR) activated by the neurotransmitter GABA
is made up of two subunits, GABA(B1) and GABA(B2). GABA(B1) binds agonists,
whereas GABA(B2) is required for trafficking GABA(B1) to the cell surface,
increasing agonist affinity to GABA(B1), and activating associated G proteins.
These subunits each comprise two domains, a Venus flytrap domain (VFT) and a
heptahelical transmembrane domain (7TM). How agonist binding to the GABA(B1)
VFT leads to GABA(B2) 7TM activation remains unknown. Here, we used a glycan
wedge scanning approach to investigate how the GABA(B) VFT dimer controls
receptor activity. We first identified the dimerization interface using a
bioinformatics approach and then showed that introducing an N-glycan at this
interface prevents the association of the two subunits and abolishes all
activities of GABA(B2), including agonist activation of the G protein. We also
identified a second region in the VFT where insertion of an N-glycan does not
prevent dimerization, but blocks agonist activation of the receptor. These data
provide new insight into the function of this prototypical GPCR and demonstrate
that a change in the dimerization interface is required for receptor
activation
- …